Дифференциальная диагностика поражения сетчатки при токсическом воздействии гидроксихлорохина

Закрыть метаданные

Коронавирусная инфекция в настоящее время является крайне актуальной темой в научном мире по причине появления нового серотипа, вызывающего состояние, идентифицируемое как тяжелый острый респираторный синдром (SARS)-COV-2. В связи с длительной историей применения при других инфекционных заболеваниях, доступностью и относительно низкой стоимостью рассмотрена возможность применения хлорохина и гидроксихлорохина in vivo и in vitro исследована способность этих препаратов подавлять возбудитель SARS-CoV-2. Несмотря на то, что исследователи отметили терапевтический потенциал этих препаратов, необходимо учитывать токсикологические аспекты, диктующие важность рационального употребления 4-аминохинолиновых производных. Данный обзор литературы посвящен анализу закономерности развития токсической ретинопатии на фоне приема гидроксихлорохина, основным принципам диагностики и дифференциальной диагностики данного состояния и других видов патологии сетчатки.

Ключевые слова:

коронавирус

гидроксихлорохин

токсическая ретинопатия

Авторы:

Будзинская М.В.

ФГБНУ «Научно-исследовательский институт глазных болезней»

Дуржинская М.Х.

ФГБНУ «Научно-исследовательский институт глазных болезней»

Даты поступления:

26.05.2020

Даты принятия в печать:

17.06.2020

Список литературы:

Jakhar D, Kaur I. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nature Medicine. 2020;26(5):632. https://doi.org/10.1038/s41591-020-0853-0
Sinha N, Balayla G. Hydroxychloroquine and covid-19. Postgraduate Medical Journal. 2020;137785. https://doi.org/10.1136/postgradmedj-2020-137785
Yao X, Ye F, Zhang M. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020; ciaa237. https://doi.org/10.1093/cid/ciaa237
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269‐271. https://doi.org/10.1038/s41422-020-0282-0
Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. Journal of Medicinal Chemistry. 2006;49(9):2845‐2849. https://doi.org/10.1021/jm0601856
Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia. Zhonghua jie he he hu xi za zhi: Chinese journal of tuberculosis and respiratory diseases. 2020;43(3):185-188. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.009
Potential Antiviral Drugs under Evaluation for the Treatment of COVID-19. Accessed March 12, 2020. https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/
US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. April 27, 2020. Accessed March 28, 2020. https://www.fda.gov/media/136537/download
US Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): Information for Clinicians on Therapeutic Options for COVID-19 Patients. Accessed March 26, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html
Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, Ling Y, Huang D, Song S, Zhang D, Qian Z, Li T, Shen Y, Lu H. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University. Medical sciences. 2020;49(2):215-221. https://doi.org/10.3785/j.issn.1008- 9292.2020.03.03
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care. 2020;57:279-283. https://doi.org/10.1016/ j.jcrc.2020.03.005
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020;20:105949. https://doi.org/10.1016/jantimicag.2020.105949
Авдеев С.Н. Временные методические рекомендации. Лекарственная терапия острых респираторных вирусных инфекци (ОРВИ) в амбулаторной практике в период эпидемии COVID-19. Версия 2. Ссылка активна на 16.04.20. https://static0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf
Shroyer NF, Lewis RA, Lupski JR. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: Is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? American Journal of Ophthalmology. 2001;131(6):761-766. https://doi.org/10.1016/s0002-9394(01)00838-8
Lee Y, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis and Rheumatology. 2016;68(1):184-90. https://doi.org/10.1002/art.39402
Grassmann F, Bergholz R, Mändl J, Jägle H, Ruether K, Weber BH. Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). BMC Ophthalmology. 2015;6(15):18. https://doi.org/10.1186/s12886-015-0008-0
Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmology. 2014;132(12):1453-1460. https://doi.org/10.1001/jamaophthalmol.2014.3459
Tanaka M, Takashina H, Tsutsumi S. Comparative assessment of ocular tissue distribution of drug-related radioactivity after chronic oral administration of C14-levofloxacin and C14-chloroquine in pigmented rats. Journal of Pharmacy and Pharmacology. 2004;56(8):977-983. https://doi.org/10.1211/0022357043932
Marmor M, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2016;123(6):1386-1394. https://doi.org/0.1016/j.ophtha.2016.01.058
Pasaoglu I, Onmez FE. Macular toxicity after short-term hydroxychloroquine therapy. Indian Journal of Ophthalmology. 2019;67(2):289-292. https://doi.org/10.4103/ijo.IJO_732_18
Hernandez Bel L, Monferrer Adsuara C, Hernandez Garfella M, Cervera Taulet E. Early macular toxicity following 2 months of hydroxychloroquine therapy. Archivos de la Sociedad Espanola de Oftalmologia. 2018;93(3):20-21. https://doi.org/10.1016/j.oftal.2017.12.004
Browning DJ. Pharmacology of Chloroquine and Hydroxychloroquine. Hydroxychloroquine and Chloroquine Retinopathy. In: Hydroxychloroquine and Chloroquine Retinopathy. New York, NY: Springer; 2014;35-63. https://doi.org/10.1007/978-1-4939-0597-3_2
Ivanina TA, Zueva MV, Lebedeva MN, Bogoslovsky AI, Bunin AJ. Ultrastructural alterations in rat and cat retina and pigment epithelium induced by chloroquine. Graefe’s Archive for Clinical and Experimental Ophthalmology. 1983;220:32-38.
Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmology. 2014;132(9):1105-1112.
Kellner S, Weinitz S, Farmand G, Kellner U. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. British Journal of Ophthalmology. 2014;98(2): 200-206. https://doi.org/10.1136/bjophthalmol-2013-303897
Chen E, Brown DM, Benz MS, Fish RH, Wong TP, Kim RY, Major JC. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the «flying saucer» sign). Clinical Ophthalmology. 2010;4:1151‐1158. https://doi.org/10.2147/OPTH.S14257
Kellner U, Agnes BR, Tillack H. Fundus Autofluorescence and mfERG for Early Detection of Retinal Alterations in Patients Using Chloroquine/Hydroxychloroquine. Investigative Ophthalmology and Visual Science. 2006; 47(8):3531-3538. https://doi.org/10.1167/iovs.05-1290
Garrity ST, Jung JY, Zambrowski O, Pichi F, Su D, Arya M, Waheed NK, Duker JS, Chetrit Y, Miserocchi E, Giuffrè C, Kaden TR, Querques G, Souied EH, Freund KB, Sarraf D. Early hydroxychloroquine retinopathy: optical coherence tomography abnormalities preceding Humphrey visual field defects. British Journal of Ophthalmology. 2019;103(11):1600-1604. https://doi.org/10.1136/bjophthalmol-2018-313350
Marmor MF. COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern? American Journal of Ophthalmology. 2020; 213:3‐4. https://doi.org/10.1016/j.ajo.2020.03.028
Pandya HK, Robinson M, Mandal N, Shah VA. Hydroxychloroquine retinopathy: A review of imaging. Indian Journal of Ophthalmology. 2015;63(7): 570-574. https://doi.org/10.4103/0301-4738.167120
Kan E, Yakar K, Demirag MD, Gok M. Macular ganglion cell-inner plexiform layer thickness for detection of early retinal toxicity of hydroxychloroquine. International Ophthalmology. 2018;38(4):1635-1640. https://doi.org/10.1007/s10792-017-0635-y
Pasadhika S, Fishman GA, Choi D, Shahidi M. Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity. Eye (London, England). 2010;24(5):756‐763. https://doi.org/10.1038/eye.2010.21
Ahn SJ, Ryu SJ, Joung JY, Lee BR. Choroidal Thinning Associated with Hydroxychloroquine Retinopathy. American Journal of Ophthalmology. 2017; 183:56-64. https://doi.org/10.1016/j.ajo.2017.08.022
Reiner A, Fitzgerald MEC, Del Mar N, Li C. Neural control of choroidal blood flow. Progress in Retinal and Eye Research. 2018;64:96-130. https://doi.org/10.1016/j.preteyeres.2017.12.001
Bulut M, Akıdan M, Gözkaya O, Erol MK, Cengiz A, Çay HF. Optical coherence tomography angiography for screening of hydroxychloroquine-induced retinal alterations. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2018;256(11):2075-2081. https://doi.org/10.1007/s00417-018-4117-3
Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology. 2015;122(1):110-116. https://doi.org/10.1016/j.ophtha.2014.07.018
Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (London, England). 2017;31(6):828-845. https://doi.org/10.1038/eye.2016.298
Querques G, Souied E. eds. Macular Dystrophies. New York, NY: Springer; 2016.
Allam RS, Abd-Elmohsen MN, Khafagy MM, Raafat KA, Sheta SM. Spectral-Domain Optical Coherence Tomography of Preclinical Chloroquine Maculopathy in Egyptian Rheumatoid Arthritis Patients. Journal of Ophthalmology. 2015;292357. https://doi.org/10.1155/2015/292357
Stokkermans TJ, Trichonas G. Chloroquine and Hydroxychloroquine Toxicity. Stat Pearls. Updated June 4, 2019. Accessed 16.04.20. https://www.ncbi.nlm.nih.gov/books/NBK537086/
van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S, Hoyng CB, Piccolino FC, Chhablani JK, Lai TYY, Lotery AJ, Larsen M, Holz FG, Freund KB, Yannuzzi LA, Boon CJF. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Progress in Retinal and Eye Research. 2019;73:100770. https://doi.org/10.1016/j.preteyeres.2019.07.003
Noupuu K, Lee W, Zernant J, Tsang SH, Allikmets R. Structural and Genetic Assessment of the ABCA4-Associated Optical Gap Phenotype. Investigative Ophthalmology and Visual Science. 2014;55(11):7217‐7226. https://doi.org/10.1167/iovs.14-14674
Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Archives of Ophthalmology. 2012;130(4):461-469. https://doi.org/10.1001/archophthalmol.2011.371
Noupuu K, Lee W, Zernant J, Greenstein VC, Tsang S, Allikmets R. Recessive Stargardt disease phenocopying hydroxychloroquine retinopathy. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2016;254(5):865-872. https://doi.org/10.1007/s00417-015-3142-8
Langwińska-Wośko E, Szulborski K, Zaleska-Żmijewska A, Szaflik J. Electrophysiological testing as a method of cone-rod and cone dystrophy diagnoses and prediction of disease progression. Documenta Ophthalmologica. 2015;130(2):103-109. https://doi.org/10.1007/s10633-015-9479-9

Закрыть метаданные